AEterna Zentaris Inc. Stock News

Aeterna Zentaris (AEZS) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $0.84 per share a year ago.

Aeterna Zentaris (AEZS) delivered earnings and revenue surprises of 9.68% and 134.43%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.

Live video webcast on Thursday , January 19 th at 3 :00 PM ET

- Vote to approve share consolidation adjourned to July 6, 2022

TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commerc

TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercia

– Data presented at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists

– Continued advancement across diversified development pipeline

uniQure (QURE) delivered earnings and revenue surprises of -49.25% and 96.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

– Company advancing development of its Autoimmunity Modifying AIM Biologicals as a potential therapeutic treatment option for Parkinson’s Disease ("PD"), a neurodegenerative movement disorder

– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin® / Macrilen™ in Europe as the Company plans to pursue even greater protection

– Live moderated video webcast fireside chat with Dr. Klaus Paulini, CEO and Giuliano La Fratta, CFO of Aeterna Zentaris, on Thursday, April 14th at 10:00 AM ET

– Company to present regarding AIM Biologicals as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD"), an orphan indication with strong unmet medical need

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -9.26% and 6%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?